Related Experiment Video
Updated: Sep 14, 2025
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
Published on: December 20, 2024
Synthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165)
John A Brailsford1, Kai Cao1, Samuel J Bonacorsi1
1Discovery and Development Sciences - Radiochemistry, Bristol Myers Squibb, Princeton, New Jersey, USA.
Abstract:
Deucravacitinib (BMS-986165) is a small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) currently approved for the treatment of moderate to severe plaque psoriasis. Tyrosine kinase 2 (TYK2) is a member of the Janus (JAK) family of non-receptor kinases that modulate the production of inflammatory cytokines. The synthesis of 14C-radiolabeled and stable-isotope labeled variants of deucravacitinib is described in this publication.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
